RESEARCH ARTICLE

Vancomycin resistant *Enterococci* and its associated factors among HIV infected patients on anti-retroviral therapy in Ethiopia

Belayneh Regasa Dadi⊙*, **Zerihun Solomon, Mheret Tesfaye**

Department of Medical Microbiology, Arba Minch University, Arba Minch, Ethiopia

* belayjanimen@gmail.com

Abstract

Background

The emergence of vancomycin resistant Enterococci (VRE) has alarmed the global community due to its tendency for colonization of the gastrointestinal tract. Human Immunodeficiency Virus (HIV) patients are colonized by vancomycin resistant Enterococci than other groups. The aim of this study was to determine the incidence of vancomycin resistant Enterococci and its associated factors among HIV infected patients on Anti-Retroviral Therapy (ART).

Methods

Institution based cross sectional study was conducted among HIV infected patients on ART at from June 1 to August 30, 2020. Socio-demographic and clinical data were collected by pre-tested structured questionnaire. Stool sample was collected and processed by standard microbiological techniques. Kirby Bauer Disc diffusion method was used to perform antimicrobial susceptibility testing. Data were entered by Epi data version 4.6.0.2 and analyzed by SPSS version 25. Bivariable and multivariable logistic regression model was used to analyze the association between dependent and independent variables. P-values in the multivariable analysis, adjusted odds ratio (AOR) and 95% confidence interval (CI) were used to determine the strength of association. P-value ≤ 0.05 was considered as significant.

Results

Enterococci spp was isolated on 123/200 (61.50%) patients. Among these isolates, the incidence of vancomycin resistant Enterococci was 11.4% [95% CI: (6.0–17.0)]. Antimicrobial susceptibility patterns against *Enterococci* showed highest rate of resistance to ampicillin (69.9%). Multidrug resistances were observed in 49.59% of *Enterococci* isolates. Study participants who had prior antibioticexposurer more than two weeks [AOR = 7.35; 95% CI: (1.2144.64)] and hospitalization for the last six months [AOR = 5.68; 95% CI: (1.09 29.74)] were significantly associated with vancomycin resistant *Enterococci*.

Conclusions

In our study high incidence of vancomycin resistant *Enterococci* was found. Previous exposure to antibiotics for more than two weeks and hospitalization for more than six months were significantly associated with vancomycin resistant *Enterococci*. The isolated *Enterococci* had variable degrees of resistance to commonly prescribed antibiotics. Therefore, periodic surveillance on antimicrobial resistance pattern, adhering to rational use of antibiotics and implementing infection prevention protocols may reduce colonization by VRE.

Introduction

A major problem with the *Enterococci* is they are very resistant to antibiotics and have ability to survive in harsh environments in community and persist in hospital settings [1]. Because of this, they become important in health facility based settings [2]. According to World Health Organization (WHO) report in 2017, vancomycin resistant Enterococci (VRE) is one of the most resistant bacteria in their "Global Priority list of antibiotic-resistant bacteria" [3]. In the same manner, the Center for Disease Control and Prevention (CDC) has classified *Enterococci* among bacteria with a threat level of serious [4]. Currently, VRE are the cause of one-third and one fifth of all health care associated infections in the United States and in some European countries respectively [5].

VRE are known in causing different enterococcal infections such as infective endocarditis, bacteremia, urinary tract infection, intra-abdominal and pelvic infections, surgical wound infections, and very rarely Central nervous system (CNS) infection. Many of these infections originate from intestinal flora of colonized individuals. VRE have different selection pressures for proliferation and rapid expansion of its resistant populations. Furthermore, few options are left for management of diseases caused by VRE, and hence causing increased mortality on infected individuals. VRE now represent approximately one third of *Enterococcus* isolates [6–17].

Asymptomatic VRE gut colonization precedes infection with susceptible hosts. Such susceptible hosts are patients who are exposed to multiple and prolonged courses of antimicrobial agents like Human Immunodeficiency virus (HIV) infected individuals, severely ill, hospitalized for long lengths of stay (LOS), living in a long-term care facility, located in close proximity to another colonized or infected patient, or hospitalized in a room previously occupied by a patient colonized with VRE. Colonization is often obtained by vulnerable hosts in an environment with increased rate of patient colonization with VRE [2, 18–26]. The prevalence of VRE was reported in Europe, Asia, Australia, South America and some African countries [1, 5, 24, 26]. However, there is no sufficient data available on the prevalence and risk factors of VRE in developing countries like Ethiopia. Therefore, this study was conducted with the aim of determining the prevalence of vancomycin resistant enterococci and its associated factors among HIV infected patients on Anti-Retroviral Therapy (ART).

Materials and methods

Study design, period and setting

The study was conducted in Arba Minch General Hospital (Arba Minch, Ethiopia) from June 1 to August 30, 2020. The hospital has ART clinic where it provides different services for HIV-infected patients. The total population of Arba Minch town from 2007 central statistical agency

(CSA) census report was 74,879, of whom 39,208 were men and 35,671 women [27]. The inclusion criteria was all HIV infected patients on ART during the study period. Exclusion criteria were HIV infected patients who don't have Parent or guardian assent if they are <18 years old and those HIV infected patients who were critically ill and unable to respond.

Sampling technique

Systematic random sampling technique was used to select the study participants. Based on the 2020 three months (June-August, 2020) data obtained during COVID-19 pandemic from Arba Minch General Hospital ART clinic, N = 366 (N = total number of study participants) HIV infected patients has visited the ART clinic. Assuming the same number of HIV- infected patients for the study period (June-August, 2020) and taking sample size of 200, the kth value (k = N/n = 366/2002) is found to be 2 [28]. The first one is selected with lottery method from 1st and 2nd patients and found to be 2nd patient. Then every 2nd patient was included.

Dependent variable was VRE gut colonization and independent variables were: Age, Sex, CD4 count, Level of hemoglobin, Previous antibiotic treatment for >2 weeks, Current visiting status (Inpatient or Outpatient), History of hospitalization in the last six months, Urinary catheterization, Co-morbid conditions (diabetes and renal failure).

Data collection and laboratory processing

A pretested well designed structured questionnaire was used to collect data from the study participants. The questionnaire was designed by reviewing different literatures and prepared in English and Amharic languages.

Upon the arrival of each study participant at ART clinic, written assent/consent was obtained. Socio-demographic and clinical data were collected by two nurses using a pretested well designed structured questionnaire through face-to-face interview. Moreover, recent CD4 count and hemoglobin level of respondents have been taken from ART clinic logbook.

Isolation and identification of *Enterococci*

Patients were instructed to collect about 2gm of the faecal specimen in a sterile wide-mouth screw capped container labeled with the unique sample number, date, and time of collection. The collected stool specimens were transported to Arba Minch University, College of Medicine and Health Sciences, Microbiology and Parasitology laboratory.

Immediately after delivery, the transported stool specimens was streaked on Bile Esculin Azide agar (BEAA) (Park Scientific Limited, 24 Low Farm Place, Moulton Park, Northampton, NN3 6HY) and incubated for 24 hours at 37˚C. Plates were observed for appearance of characteristic growth with brown-black colored colonies in the medium and dark halo centers. Typical characteristic colonies were selected randomly for characterization and presumptive identification of *Enterococci* by Gram stains, Catalase test, Salt tolerance test and Heat tolerance test [29].

The antimicrobial susceptibility testing was performed using Kirby Bauer disc diffusion method according to Clinical Laboratory Standards Institute guidelines (CLSI) [30]. After a pure colony was obtained, a loop full of bacteria were taken, transferred to a tube containing 5 ml of sterile normal saline (0.85% NaCl) and mixed gently until it formed a homogenous suspension. The turbidity of the suspension was determined by comparison with 0.5 McFarland standards. A sterile swab was dipped into the suspension, and excess suspension was removed by pressing the swab against the wall of the tube. The entire surface of Muller Hinton Agar plate was uniformly flooded with suspensions and allowed to dry for about 3–5 minutes. The antimicrobial impregnated disks were placed by using sterile forceps at least 24 mm away from

each other to avoid the overlapping zone of inhibition. The disks were placed on agar plates and allowed to stand for 30 minutes to dissolve the antibiotics in the media [16]. The plates were then inverted and incubated at 37°c for 16–18 hours and inhibition zone was measured using a ruler.

In the case of vancomycin, the plates were inverted and incubated at 37°c, and held a full 16–18 hours for accurate detection of resistance. Zones were examined using transmitted light; the presence of a haze or any growth within the zone of inhibition indicates resistance for vancomycin. Grades of susceptibility pattern were recognized as sensitive, intermediate and resistant by comparison of zone of inhibition according to the 2018 CLSI guidelines [30].

Antimicrobial susceptibility patterns of *Enterococci* were also assessed against the following antibiotic discs: Penicillin (10 IU), Ampicillin (10 μg), Tetracycline (30μg), Doxycycline (30μg), Ciprofloxacin (5μg), Vancomycin (30 μg), Erythromycin (15μg) and Chloramphenicol (30μg). Interpretations of results were made according to CLSI (30). Antibiotics were selected based on CLSI recommendation, local availability (in health facility) and feasibility (cost and method of antimicrobial susceptibility test).

Data quality assurance

A pretest was done on 5% (n = 10) HIV infected individuals. Quality control measures were implementing throughout the entire process of data collection and laboratory work. Training was given for data and sample collectors concerning on the research objective, data collection tools, sample collection procedures, and infection prevention protocols to be taken related with COVID-19 Pandemic. Standard Operating Procedures (SOP) were prepared and implemented strictly. All culture media were prepared following the manufacturer's instruction and sterility of the culture media was tested by incubating 5% of the batch at 35–37˚C overnight for evaluation of possible contamination. Standard control strains *E. faecalis* ATCC 29212 and *Staphylococcus aureus* ATCC 25923 were used as a positive control.

Statistical analysis

Data were checked for its completeness, entered by Epi data version 4.6.0.2 software, and analyzed by SPSS version 25. The fitness of the model was checked by Hosmer-Lemeshow goodness of fit test. Bivariable and multivariable logistic regression model was used to analyze the association between dependent and independent variables. Those variables with P-value < 0.25 in bivariate analysis were considered as candidate for further multivariable analysis. P-values in the multivariable analysis, adjusted odds ratio (AOR) and 95% confidence interval (CI) were used to determine the strength of association. P-value <0.05 was considered as statistically significant.

Ethics approval and consent to participate

Ethical clearance was obtained from Institutional Review Board (IRB) of Arba Minch University, College of Medicine and Health Sciences, and letter of permission to conduct the study was written to Arba Minch General Hospital. Official permission from Arba Minch General Hospital and an informed written assent/consent from each study participants (assent of those <18 age group from their family or guardian) were obtained.

All information that identifies study subjects were given code numbers and were kept confidential. The purpose of the study was clearly described to the study participants and the specimens collected from the patients were analyzed for the intended purpose only. For each confirmed resistant case, the responsible clinicians of the patient were informed for appropriate management.

Results

Socio-demographic characteristics of study participants

A total of 200 study participants were enrolled in this study. Among these the ratio of male to female was 1:1. The mean age and standard deviation was 38.68 ± 10.97 ranging from 18–67 years. More than three fourth of the study participants 154 (77.0%) came from urban settings (**Table 1**).

Clinical characteristics of study participants

The clinical data showed that majority of the participants 187 (93.5%) were outpatients and 168 (84.0%) of the participants had CD4 count >350. Less than half of the respondents 83 (41.5%) had low hemoglobin level and 94 (47.0%) had history of previous antibiotic use for <2 weeks. Majority of the study participants 174 (87.0%) didn't have previous history of hospitalization in the last six months and 180 (90.0%) didn't have history of previous catheterization. Likewise, majority of the respondents 191 (95.5%) and 193 (96.5%) didn't have Diabetes Mellitus and Renal failure respectively (**Table 2**).

Incidence of vancomycin resistant *Enterococcus*

From the total of 200 study participants, *Enterococci* species was isolated from123 (61.50%) patients. Among these isolates, 14 (11.4%) were vancomycin resistant (95% CI: 6.0–17.0%).

Antimicrobial resistance profile of isolated *Enterococci*

Among 123 *Enterococci* isolates tested for commonly prescribed antimicrobial agents the highest rate of resistance was observed against ampicillin in which more than two thirds 86 (69.9%) of the isolates were resistant (**Fig 1**).

Table 1. Socio-demographic characteristics of study participants attending ART clinic at Arba Minch General Hospital, Southern Ethiopia October 2020 (N = 200).

Variables	Frequency	Percentage (%)
Sex		
Males	100	50.0
Females	100	50.0
Age		
≤20	12	6.0
21–30	30	15.0
31–40	78	39.0
41–50	47	23.5
≥51	33	16.5
Residence		
Rural	46	23.0
Urban	154	77.0
Educational Status		
Unable to read and write	17	8.5
Able to read and write	42	21.0
Primary (1–8)	62	31.0
Secondary (9–12)	62	31.0
College and above	17	8.5

https://doi.org/10.1371/journal.pone.0251727.t001

Table 2. Clinical characteristics of study participants attending ART clinic at Arba Minch General Hospital, Southern Ethiopia October 2020 (N = 200).

| Visiting Status	Frequency	Percentage
Outpatient	187	93.5
Inpatient	13	6.5
CD$_4$+ Count		
≤350	32	16.0
>350	168	84.0
Hemoglobin Level		
Low	83	41.5
Normal	111	55.5
High	6	3.0
Previous Antibiotic Treatment		
Never	76	38.0
≥2 weeks	30	15.0
<2 weeks	94	47.0
History of hospitalization in the last six months		
No	174	87.0
Yes	26	13.0
History of previous catheterization		
No	180	90.0
Yes	20	10.0
Comorbid condition (Diabetes)		
No	191	95.5
Yes	9	4.5
Comorbid condition (Renal failure)		
No	193	96.5
Yes	7	3.5

https://doi.org/10.1371/journal.pone.0251727.t002

Multidrug resistances (MDR) were observed in slightly less than half 61 (49.59%) of *Enterococci* isolates and less than one tenth 11 (8.94%) of the isolates were resistant to all antimicrobials tested. All VRE isolates were MDR (**Table 3**).

Factors associated with vancomycin resistant *Enterococcus* gut colonization

Factors independently associated with VRE gut colonization on bivariable analysis, and fit into a multivariable logistic regression model were sex, visiting status, history of catheterization, previous antibiotics treatment, history of hospitalization in the last six months and presence of Diabetes Mellitus (**Tables 4 and 5**).

Discussion

The hasty emergence and the increasing incidence of colonization with VRE have become challenging healthcare problems that have caused serious concern to health care providers and health authorities [2]. In the present study, the prevalence of VRE among HIV infected patients was 11.4% (95% CI: 6.0–17.0%). This prevalence rate was consistent with other studies conducted in, West Amhara, Ethiopia (7.7%) [2] Gondar, Northwest Ethiopia (7.8%) [18], where these studies were done on HIV positive patients and also comparable with studies done on HIV status patients not known in Addis Ababa, Ethiopia (6.7%) [31] and South Africa (14.5%) [21]. However, the prevalence of VRE in our study is lower than the report from

Fig 1. Antimicrobial resistance patterns of isolated *Enterococcus* spp among clients attending ART clinic at Arba Minch General Hospital, Southern Ethiopia October 2020 (n = 123).

Ireland (44.1%) [4], Germany (26.1%) [32] Brazil (23.4%) [1], India (19.6%) [33], Saud Arabia (17.3%) [5] and Iraq (46.4%) [17] where these studies were conducted on the population where HIV status not determined. The lower prevalence in the present study might be due to the variation in study settings in which most of the previous countries have been using oral and intravenous vancomycin massively for human diseases [34, 35], and variation in study participants where the previous studies participants were hospitalized patients and critically ill patients in ICU who were frequently exposed to different antibiotics and experienced insertion of external devices like catheter [7]. On the other hand, the prevalence in our study is higher than studies conducted in USA (4.7%) [36], Nigeria (4.07%) [37] and Ethiopia (5.9%) [16]. The gradual increase and clonal expansion in the prevalence of VRE might have contributed to this higher prevalence [32, 38].

Enterococci isolates showed various resistances to the tested antibiotics; namely, 69.9% to ampicillin, 54.5% to penicillin, 49.6% to erythromycin, 59.3% to tetracycline, 28.5% to

Table 3. Profile of multidrug resistance pattern of VRE isolates among clients attending ART clinic at Arba Minch General Hospital, Southern Ethiopia October 2020 (n = 14).

Resistance rate	Combination of Antibiotics	No. (%) of isolates tested
R4	G, P, TTC, MAC	14 (100)
R5	(G, P, TTC, MAC) + F	2 (14.28)
R6	(G, P, TTC, MAC) + F+ PH	11 (78.58)

Key; G-glycopeptides (vancomycin), P-penicillins (ampicillin and/or penicillin), TTC-tetracyclines (tetracycline and/or doxycycline), MAC-macrolides (erythromycin), F-fluoroquinolones (ciprofloxacin), PH-phenicols (chloramphenicol), and R4-R6 Number of categories of antibiotics resistance from 4 to 6, respectively

Table 4. Bivariable logistic regression analysis on factors affecting vancomycin resistant *Enterococci* among clients attending ART clinic at Arba Minch General Hospital, Southern Ethiopia October 2020.

Characteristics	Categories	VRE gut colonization		COR	P-value
		Yes, N (%)	No, N (%)		
Sex	Females	4 (6.8)	55 (93.2)	**0.39**	**0.133**＊
	Males	10 (15.6)	54 (84.4)	1	
Residence	Urban	11 (11.6)	84 (88.4)	1.09	0.899
	Rural	3 (10.7)	25 (89.3)	1	
Visiting status	Inpatient	3 (30.0)	7 (70.0)	**3.97**	**0.069**＊
	Outpatient	11 (9.7)	102 (90.3)	1	
CD4 count	≤350	2 (11.8)	15 (88.2)	1.04	0.957
	>350	12 (11.3)	94 (88.7)	1	
Previous Antibiotic Treatment	Never	2 (4.9)	39 (95.1)	1	
	≥2 weeks	8 (40.0)	12 (60.0)	**13.00**	**0.003**＊
	<2 weeks	4 (6.5)	58 (93.5)	1.34	0.739
History of hospitalization in the last six months	Yes	6 (37.5)	10 (62.5)	**7.43**	**0.002**＊
	No	8 (7.5)	99 (92.5)	1	
History of previous catheterization	Yes	4 (25.0)	12 (75.0)	**3.23**	**0.078**＊
	No	10 (9.3)	97 (90.7)	1	
Diabetes Mellitus	Yes	2 (28.6)	5 (71.4)	**3.48**	**0.163**＊
	No	12 (10.3)	104 (89.7)	1	

＊Variables which passed bivariable logistic regression analysis at cut off value <0.25

https://doi.org/10.1371/journal.pone.0251727.t004

ciprofloxacin and 21.1% to chloramphenicol. These findings are comparable with studies conducted in India 64.9% [33] and Ethiopia 66.7% [39] for ampicillin; Ethiopia 64.9% [40], 68% [39] for tetracycline; and Brazil 45.7% [1] and Ethiopia 42.7% [9] 53.3% [31] for erythromycin. However, the resistance profiles in our study is lower than previous studies in India for tested antibiotics 75.9% for penicillin, 84.5% for tetracycline, 95.5% for ciprofloxacin, 92.1% for

Table 5. Multivariable logistic regression analysis on factors affecting vancomycin resistant *Enterococci* among clients attending ART clinic at Arba Minch General Hospital, Southern Ethiopia October 2020.

Characteristics	Categories	VRE isolates		AOR (95%CI)	P-value
		Yes, N (%)	No, N (%)		
Sex	Females	4 (6.8)	55 (93.2)	0.27 (0.06–1.25)	0.093
	Males	10 (15.6)	54 (84.4)	1	
Visiting status	Inpatient	3 (30.0)	7 (70.0)	1.13 (0.15–8.43)	0.904
	Outpatient	11 (9.7)	102 (90.3)	1	
Previous Antibiotic Treatment	Never	2 (4.9)	39 (95.1)	1	
	≥2 weeks	8 (40.0)	12 (60.0)	**7.35 (1.21–44.64)**	**0.030**＊＊
	<2 weeks	4 (6.5)	58 (93.5)	1.08 (0.17–6.80)	0.936
History of hospitalization in the last six months	Yes	6 (37.5)	10 (62.5)	**5.68 (1.09–29.74)**	**0.040**＊＊
	No	8 (7.5)	99 (92.5)	1	
History of previous catheterization	Yes	4 (25.0)	12 (75.0)	1.38 (0.27–7.03)	0.701
	No	10 (9.3)	97 (90.7)	1	
Diabetes Mellitus	Yes	2 (28.6)	5 (71.4)	1.81 (0.21–15.36)	0.588
	No	12 (10.3)	104 (89.7)	1	

＊＊Significant in multivariable logistic regression at p-value <0.05

https://doi.org/10.1371/journal.pone.0251727.t005

erythromycin and 42.3% for chloramphenicol [33]; Uganda 69.4% [15] and Ethiopia 77.3% [41] for tetracycline; and Iraq (85.7%) [17], Uganda (72%) [15] and Ethiopia 63.2% [41] erythromycin; These lower drug resistance patterns might be due to variations in sample size, methodology and study participants where most of the participants in the previous studies were hospitalized patients who were taking different antibiotics that might have been contributed for emergence of high rate of drug resistance.

On the other hand, the antibiotic resistance profile in our study is higher than studies conducted in Iran 41.2% [42], Brazil 0% [1], Uganda 1.4% [15] and Ethiopia 36% [41] for ampicillin; Brazil 32.6% [1] and Ethiopia 37.7% [2] for tetracycline; and Brazil 10.9% [1] for chloramphenicol. The high drug resistance patterns might be due to overuse or misuse of antibiotics and inappropriate antibiotics prescription which is very common practice in Ethiopia. Additional reasons for high drug resistance might be extensive antibiotics use of antibiotics for agricultural purpose, mutation and gene transfer among bacteria [4].

Moreover, the present study also showed that 49.6% of *Enterococci* isolates were multidrug resistant. This result is lower than the findings in Iraq (85.7%) [17] and Ethiopia 80.8% [41]. In contrary, the result is higher than the finding in Ethiopia 29.5% [16]. The discrepancy of the result might be due to variation in geographical distribution of strain, trend and frequency of antibiotic prescription, community drug usage practice.

Our study showed that HIV patients who were previously exposed to antibiotics for more than two weeks were seven times more likely to be colonized with VRE as compared with HIV patients who never exposed to antibiotics previously [AOR = 7.35; 95% CI: (1.21–44.64); P-value = 0.030]. This result is in agreement with other studies conducted in Brazil [1], South Korea [43], Egypt [44], and Ethiopia [2]. The reason might be a prior exposure to antibiotics for a prolonged duration can cause VRE colonization due to the fact that the antibiotics exert selective pressure to Enterococci and alter the competing microbial flora in the GI tract allowing VRE to predominate as evidenced by other studies [7, 34].

The present study showed that HIV patients who had history of hospitalization for the last six months were six times more likely to be colonized with VRE as compared with HIV patients who didn't have history of hospitalization for the last six months [AOR = 5.68; 95% CI: (1.09–29.74); P-value = 0.040]. The finding is consistent with previous studies done in USA [36], South Korea [43] and Ethiopia [2]. The reason might be VRE have been isolated from virtually every object within patient rooms since they are intrinsically resistant to several commonly used antibiotics in hospital and have ability to acquire resistance genes. Besides, they are ubiquitous in their presence and have high survivability on dry surfaces, thereby causing high VRE transmission rates within healthcare facilities [7, 9].

Limitations of the study

The isolated *Enterococci* were not identified to species level; molecular characterization and MIC were not done due to resource limitation and budget constraints.

Conclusions

In our study high incidence of vancomycin resistant Enterococci was found. Previous exposure to antibiotics for more than two weeks and previous hospitalization for more than six months were significant factors for vancomycin resistant enterococci gut colonization. The study also showed that the isolated *Enterococci* had variable degrees of resistance to commonly prescribed antibiotics.

Therefore, periodic surveillance on antimicrobial resistance pattern, adhering to rational use of antibiotics and implementing infection prevention protocols may reduce colonization by VRE.

Supporting information

S1 File.
(PDF)

S2 File.
(DOCX)

Acknowledgments

The authors would like to thank those who were involved in this research.

Author Contributions

Conceptualization: Belayneh Regasa Dadi, Zerihun Solomon, Mheret Tesfaye.

Data curation: Belayneh Regasa Dadi.

Formal analysis: Belayneh Regasa Dadi, Zerihun Solomon.

Funding acquisition: Belayneh Regasa Dadi.

Investigation: Belayneh Regasa Dadi, Zerihun Solomon, Mheret Tesfaye.

Methodology: Belayneh Regasa Dadi, Zerihun Solomon, Mheret Tesfaye.

Project administration: Belayneh Regasa Dadi, Mheret Tesfaye.

Resources: Belayneh Regasa Dadi, Mheret Tesfaye.

Software: Belayneh Regasa Dadi, Mheret Tesfaye.

Supervision: Belayneh Regasa Dadi, Mheret Tesfaye.

Validation: Belayneh Regasa Dadi, Mheret Tesfaye.

Visualization: Belayneh Regasa Dadi.

Writing – original draft: Belayneh Regasa Dadi, Zerihun Solomon, Mheret Tesfaye.

Writing – review & editing: Belayneh Regasa Dadi, Zerihun Solomon, Mheret Tesfaye.

References

1. Batistão DW, Gontijo-Filho PP, Conceição N, Oliveira AG, Ribas RM. Risk factors for vancomycin-resistant enterococci colonisation in critically ill patients. *Mem Inst Oswaldo Cruz*. 2012; 107:57–63. https://doi.org/10.1590/s0074-02762012000100008 PMID: 22310536

2. Agegne M, Abera B, Derbie A, Yismaw G, Shiferaw MB. Magnitude of Vancomycin-Resistant Enterococci (VRE) Colonization among HIV-Infected Patients Attending ART Clinic in West Amhara Government Hospitals. *Int J Microbiol*. 2018;1–7. https://doi.org/10.1155/2018/7510157 PMID: 30693035

3. Tacconelli E. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. WHO. 2017.

4. Ventola CL. The Antibiotic Resistance Crisis: Part 1: Causes and Threats. *P T*. 2015; 40(4):277–283. PMID: 25859123

5. Alotaibi FE, Bukhari EE. Emergence of Vancomycin-resistant Enterococci at a Teaching Hospital, Saudi Arabia. *Chin Med J (Engl)*. 2017; 130:340–346. https://doi.org/10.4103/0366-6999.198923 PMID: 28139519

6. Emaneini M, Hosseinkhani F, Jabalameli F, Nasiri MJ, Dadashi M, Pouriran R, et al. Prevalence of vancomycin-resistant Enterococcus in Iran: a systematic review and meta-analysis. *Eur J Clin Microbiol Infect Dis*. 2016; 35:1387–92. https://doi.org/10.1007/s10096-016-2702-0 PMID: 27344575

7. Alevizakos M, Gaitanidis A, Nasioudis D, Tori K, Flokas ME, Mylonakis E. Colonization With Vancomycin-Resistant Enterococci and Risk for Bloodstream Infection Among Patients With Malignancy: A

Systematic Review and Meta-Analysis. *Open Forum Infect Dis*. 2016 Dec 7; 4(1):ofw246. https://doi.org/10.1093/ofid/ofw246 PMID: 28480243

8. Susan L Fraser CJD, Robert A Salata. Vancomycin Resistant Enterococcal Infections: Background, Pathophysiology, Epidemiology. *Medscape*. 2018; 97(4):223–227.

9. Murray PR, Rosenthal KS, Pfaller MA. Medical microbiology. 2016. 8th edition. Philadelphia, PA: Elsevier. USA

10. Nilsson O. Vancomycin resistant enterococci in farm animals–occurrence and importance. *Infect Ecol Epidemiol*. 2012; 2:16959. https://doi.org/10.3402/iee.v2i0.16959 PMID: 22957131

11. Sood S, Malhotra M, Das BK, Kapil A. Enterococcal infections & antimicrobial resistance. *Indian J Med Res*. 2008; 128:111–121. PMID: 19001673

12. Crank C, O'Driscoll. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. *Infect Drug Resist*. 2015; 8:217–230. https://doi.org/10.2147/IDR.S54125 PMID: 26244026

13. Carroll KC, Hobden JA, Miller S, Morse SA, Mietzner TA, Detrick B, et al. Jawetz, Melnick & Adelberg's medical microbiology. 2016. 27th edition. New York: Mcgraw-Hill Education. USA

14. Faron ML, Ledeboer NA, Buchan BW. Resistance Mechanisms, Epidemiology, and Approaches to Screening for Vancomycin-Resistant Enterococcus in the Health Care Setting. *J Clin Microbiol*. 2016; 54:2436–2447. https://doi.org/10.1128/JCM.00211-16 PMID: 27147728

15. Kateete DP, Edolu M, Kigozi E, Kisukye J, Baluku H, Mwiine FN, et al. Species, antibiotic susceptibility profiles and van gene frequencies among enterococci isolated from patients at Mulago National Referral Hospital in Kampala, Uganda. *BMC Infect Dis*. 2019; 19:486. https://doi.org/10.1186/s12879-019-4136-7 PMID: 31151413

16. Ali S, Alemayehu M, Dagnew M, Gebrecherkos T. Vancomycin-Resistant Enterococci and Its Associated Risk Factors among HIV-Positive and -Negative Clients Attending Dessie Referral Hospital, Northeast Ethiopia. *Int J Microbiol*. 2018;1–9. https://doi.org/10.1155/2018/4753460

17. Al-Dahmoshi HOM, Rabeea HWS, Aridhee ASA, Al-Khafaji NSK, Al-Allak MH, Lazm AM, et al. Phenotypic Investigation of Vancomycin, Teicoplanin and Linezolid Resistance Among Enterococcus spp. Isolated from Children Diarrhea. *J Pure Appl Microbiol*. 2019; 13(1):531–6.

18. Abebe W, Endris M, Tiruneh M, Moges F. Prevalence of vancomycin resistant Enterococci and associated risk factors among clients with and without HIV in Northwest Ethiopia: a cross-sectional study. *BMC Public Health*. 2014; 14:185. https://doi.org/10.1186/1471-2458-14-185 PMID: 24555580

19. Amberpet R, Sistla S, Parija SC, Rameshkumar R. Risk factors for intestinal colonization with vancomycin resistant enterococci' A prospective study in a level III pediatric intensive care unit. *J Lab Physicians*. 2018; 28:89–94. https://doi.org/10.4103/JLP.JLP_32_17 PMID: 29403213

20. Axelrad JE, Lebwohl B, Cuaresma E, Cadwell K, Green PHR, Freedberg DE. Gut colonization with vancomycin-resistant Enterococcus and risk for subsequent enteric infection. *Gut Pathog*. 2018; 10:28. https://doi.org/10.1186/s13099-018-0259-4 PMID: 30002733

21. Tatsing Foka FE, Kumar A, Ateba CN. Emergence of vancomycin-resistant enterococci in South Africa: Implications for public health. *South Afr J Sci*. 2018; 114(9/10). https://doi.org/10.17159/sajs.2018/4508

22. Orsi GB, Ciorba V. Vancomycin resistant enterococci healthcare associated infections. *Ann Ig*. 2013; 25:485–492. https://doi.org/10.7416/ai.2013.1948 PMID: 24284534

23. Rameshkumar MR, Arunagirinathan N. Drug-Resistant Bacterial Infections in HIV Patients. *Intech Open*. 2018; 98(5). https://doi.org/10.1016/j.jgar.2018.10.019 PMID: 30389636

24. Kwobah C, Ali I, Koskei P, Chumba D, Emonyi W, Mwangi A, et al. Antibiotic Sensitivity Patterns Among Postmortem Bacterial Isolates From HIV-Infected Patients in Western Kenya: A Cross-sectional Descriptive Study. *J Dis Glob Health*. 2015; 3:73–82.

25. Chinnambedu RS, Marimuthu RR, Sunil SS, Amrose P, Ramachandran V, Pachamuthu B. Changing antibiotic resistance profile of Staphylococcus aureus isolated from HIV patients (2012–2017) in Southern India. *J Infect Public Health*. 2020; 13(1):75–9. https://doi.org/10.1016/j.jiph.2019.06.015 PMID: 31402312

26. Remschmidt C, Schröder C, Behnke M, Gastmeier P, Geffers C, Kramer TS. Continuous increase of vancomycin resistance in enterococci causing nosocomial infections in Germany-10 years of surveillance. *Antimicrob Resist Infect Control*. 2018; 7:54. https://doi.org/10.1186/s13756-018-0353-x PMID: 29760912

27. Census 2007. Southern Peoples, Nations and Nationalities Region Archived November 13, 2012, at the Way back Machine.

28. Naing L, Winn T, Rusli BN. Practical Issues in Calculating the Sample Size for Prevalence Studies. *Arch Orof Sci* 2006; 1:9–14.

29. Bile Esculin Azide Agar ISO Formato 30 Plates [Internet]. [cited 2021 Jan 24].

30. Clinical and Laboratory Standards Institute, Performance Standards for Antimicrobial Susceptibility Testing. CLSI. 2018. 28th edition, Wayne, PA, USA

31. Ferede ZT, Tullu KD, Derese SG, Yeshanew AG. Prevalence and antimicrobial susceptibility pattern of Enterococcus species isolated from different clinical samples at Black Lion Specialized Teaching Hospital, Addis Ababa, Ethiopia. *BMC Res Note*s 2018; 11:793. https://doi.org/10.1186/s13104-018-3898-0 PMID: 30400980

32. Markwart R, Willrich N, Haller S, Noll I, Koppe U, Werner G, et al. The rise in vancomycin-resistant Enterococcus faecium in Germany: data from the German Antimicrobial Resistance Surveillance (ARS). *Antimicrob Resist Infect Control*. 2019; 8:147. https://doi.org/10.1186/s13756-019-0594-3 PMID: 31485325

33. Deshpande VR, Karmarkar MG, Mehta PR. Prevalence of multidrug-resistant enterococci in a tertiary care hospital in Mumbai, India. *J Infect Dev Ctries*. 2013; 7:155–158. https://doi.org/10.3855/jidc.3018 PMID: 23416663

34. Flokas ME, Karageorgos SA, Detsis M, Alevizakos M, Mylonakis E. Vancomycin-resistant enterococci colonisation, risk factors and risk for infection among hospitalised paediatric patients: a systematic review and meta-analysis. *Int J Antimicrob Agents*. 2017; 49:565–572. https://doi.org/10.1016/j.ijantimicag.2017.01.008 PMID: 28336313

35. Cattoir V, Leclercq R. Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce? *J Antimicrob Chemother*. 2013; 68(4):731–42. https://doi.org/10.1093/jac/dks469 PMID: 23208830

36. Achenbach C, Flores E, Ferrell P, Pitrak D, Weber SG. Prevalence of and Risk Factors for Colonization With Vancomycin-Resistant Enterococcus Among Human Immunodeficiency Virus–Positive Outpatients. *Infect Control Hosp Epidemiol*. 2006; 27:102–104. https://doi.org/10.1086/499391 PMID: 16528868

37. Ekuma AE, Oduyebo OO, Efunshile AM, Konig B. Surveillance for vancomycin resistant enterococci in a tertiary institution in south western Nigeria. *Afr J Infect Dis*. 2016; 10(2):121–126. https://doi.org/10.21010/ajid.v10i2.8 PMID: 28480447

38. Buetti N, Wassilew N, Rion V, Senn L, Gardiol C, Widmer A, et al. Emergence of vancomycin-resistant enterococci in Switzerland: a nation-wide survey. *Antimicrob Resist Infect Control*. 2019; 8:16. https://doi.org/10.1186/s13756-019-0466-x PMID: 30675343

39. Yilema A, Moges F, Tadele S, Endris M, Kassu A, Abebe W, et al. Isolation of enterococci, their antimicrobial susceptibility patterns and associated factors among patients attending at the University of Gondar Teaching Hospital. *BMC Infect Dis*. 2017; 17:276. https://doi.org/10.1186/s12879-017-2363-3 PMID: 28412932

40. Abamecha A, Wondafrash B, Abdissa A. Antimicrobial resistance profile of Enterococcus species isolated from intestinal tracts of hospitalized patients in Jimma, Ethiopia. *BMC Res Notes*. 2015; 8(1):213. https://doi.org/10.1186/s13104-015-1200-2 PMID: 26036911

41. Toru M, Beyene G, Kassa T, Gizachew Z, Howe R, Yeshitila B. Prevalence and phenotypic characterization of Enterococcus species isolated from clinical samples of pediatric patients in Jimma University Specialized Hospital, south west Ethiopia. *BMC Res Notes*. 2018; 11:281. https://doi.org/10.1186/s13104-018-3382-x PMID: 29739441

42. Anvarinejad M, Pouladfar G, Japoni A, Bolandparvaz S, Satiary Z, Mardaneh J. Diabetic Foot Infections: Antibiotic Susceptibility Patterns and Determination of Antibiotic Cross-Resistance in Clinical Isolates of Enterococcus Species During 2012–2014 in Shiraz, Iran. *Arch Pediatr Infect Dis*. 2016: 5(2). https://doi.org/10.5812/pedinfect.37680

43. Kee SY, Park CW, Lee JE, Kwon YJ, Pyo HJ, et al. Healthcare-associated risk factors of vancomycin-resistant Enterococci colonization among outpatients undergoing hemodialysis. *Jpn J Infect Dis*. 2012; 65(1):57–60. PMID: 22274159

44. Moemen D, Tawfeek D, Badawy W. Healthcare-associated vancomycin resistant Enterococcus faecium infections in the Mansoura University Hospitals intensive care units, Egypt. *Braz J Microbiol*. 2015; 46(3):777–783. https://doi.org/10.1590/S1517-838246320140403 PMID: 26413060